ST交昂(600530) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥75,550,297.09, representing a decrease of 17.28% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥3,319,302.29, a decline of 328.40% year-over-year[4]. - The net cash flow from operating activities was -¥22,718,736.39, reflecting a decrease of 321.86% compared to the previous year[4]. - Basic earnings per share were -¥0.004, down 314.17% from the same quarter last year[4]. - The company reported a net loss of CNY 679,673,041.71 for Q1 2024, compared to a net loss of CNY 676,353,739.42 in Q1 2023[13]. - In Q1 2024, the company reported a net profit of -2,167,529.60 yuan, a significant decline compared to a net profit of 3,379,802.30 yuan in Q1 2023[17]. - The company recorded a total revenue from sales of goods and services of 79,332,571.77 yuan in Q1 2024, down from 96,496,714.59 yuan in Q1 2023, indicating a decline of about 17.8%[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥780,613,881.84, a decrease of 4.23% from the end of the previous year[4]. - Total assets decreased to CNY 780,613,881.84 as of March 31, 2024, from CNY 815,095,058.94 at the end of 2023, a reduction of 4.2%[13]. - Total liabilities decreased to CNY 443,602,139.67 as of March 31, 2024, from CNY 475,915,787.16 at the end of 2023, a decline of 6.8%[13]. - Current liabilities totaled CNY 275,095,479.87 as of March 31, 2024, down from CNY 302,137,762.57 at the end of 2023, a decrease of 9.0%[12]. - Non-current assets increased to CNY 565,721,447.65 as of March 31, 2024, compared to CNY 543,343,771.44 at the end of 2023, an increase of 4.1%[12]. Shareholder Information - The company had a total of 19,911 common shareholders at the end of the reporting period[8]. - The largest shareholder, Dazhong Transportation Group Co., Ltd., held 14.48% of the shares[8]. - There are no significant changes in the top 10 shareholders or their shareholding status compared to the previous period[9]. Cash Flow and Expenses - Cash and cash equivalents as of March 31, 2024, were CNY 106,013,334.71, down from CNY 164,096,632.69 at the end of 2023, representing a decline of 35.3%[11]. - The company's cash flow from operating activities showed a net outflow of -22,718,736.39 yuan in Q1 2024, compared to a net inflow of 10,240,053.62 yuan in Q1 2023[21]. - Cash and cash equivalents at the end of Q1 2024 were 106,013,334.71 yuan, down from 135,781,873.43 yuan at the end of Q1 2023, reflecting a decrease of approximately 22%[22]. - The company incurred a total of 54,204,624.01 yuan in cash outflows from financing activities in Q1 2024, slightly lower than 54,609,344.31 yuan in Q1 2023[22]. - The company reported an investment activity cash flow net outflow of -1,317,820.51 yuan in Q1 2024, compared to -5,014,737.81 yuan in Q1 2023, showing an improvement in investment cash flow[21]. Operational Challenges - The decline in net profit was primarily due to decreased revenue in the health products segment and increased management expenses[6]. - The total operating costs decreased from 83,892,847.43 yuan in Q1 2023 to 76,561,612.96 yuan in Q1 2024, representing a reduction of approximately 8.5%[17]. - Research and development expenses dropped from 3,094,219.57 yuan in Q1 2023 to 965,476.30 yuan in Q1 2024, a decrease of about 68.8%[17]. - The company experienced a credit impairment loss of 80,416.26 yuan in Q1 2024, a significant recovery from a loss of -9,201,094.41 yuan in Q1 2023[17]. - The company has not reported any new product launches or significant technological advancements during this quarter[10].